{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:17:32Z","timestamp":1717373852515},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,2]]},"DOI":"10.7759\/cureus.61540","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T20:17:53Z","timestamp":1717359473000},"source":"Crossref","is-referenced-by-count":0,"title":["Favorable Radiographic Response in a Patient With an Oligodendroglioma Treated With Azacitidine and Venetoclax for Acute Myeloid Leukemia"],"prefix":"10.7759","author":[{"given":"Mauricio","family":"Perez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Barrionuevo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim M","family":"Baehring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119196235.ch62","article-title":"Diffuse Low-Grade Gliomas","author":"Bush NA","year":"2017","unstructured":"Bush NA, Yang D, Clarke J, Hass-Kogan D. Diffuse Low-Grade Gliomas. Textbook of Uncommon Cancer . Raghavan D, Ahluwalia MS, Blanke, et al. CD,  (ed): 2017. 888-98. 10.1002\/9781119196235.ch62"},{"key":"ref2","unstructured":"National Cancer Institute, Oligodendroglioma and Other IDH-Mutated Tumors. Diagnosis and Treatment. (2023). Accessed: November 10, 2023: https:\/\/www.cancer.gov\/rare-brain-spine-tumor\/tumors\/oligodendroglioma."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox158","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014","volume":"19","author":"Ostrom QT","year":"2017","unstructured":"Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017, 19:v1-v88. 10.1093\/neuonc\/nox158","journal-title":"Neuro Oncol"},{"key":"ref4","article-title":"Neuro-Oncology Compendium for the Boards and Clinical Practice","author":"Mrugala MM","year":"2023","unstructured":"Mrugala MM, Gatson NT, Clarke JL, Kurz SC, Nevel KS. Neuro-Oncology Compendium for the Boards and Clinical Practice . Oxford University Press, New York; 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner JC","year":"2016","unstructured":"Buckner JC, Shaw EG, Pugh SL, et al.. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016, 374:1344-55. 10.1056\/NEJMoa1500925","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03765-z","article-title":"PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression","volume":"153","author":"Weller J","year":"2021","unstructured":"Weller J, Katzendobler S, Karschnia P, et al.. PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. J Neurooncol. 2021, 153:283-91. 10.1007\/s11060-021-03765-z","journal-title":"J Neurooncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5202-98","article-title":"Procarbazine, lomustine, and vincristine (PCV) regimen for central nervous system tumors","volume":"52","author":"Solimando DA Jr","year":"2017","unstructured":"Solimando DA Jr, Waddell JA. Procarbazine, lomustine, and vincristine (PCV) regimen for central nervous system tumors. Hosp Pharm. 2017, 52:98-104. 10.1310\/hpj5202-98","journal-title":"Hosp Pharm"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1992.76.5.0741","article-title":"The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy","volume":"76","author":"Glass J","year":"1992","unstructured":"Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg. 1992, 76:741-5. 10.3171\/jns.1992.76.5.0741","journal-title":"J Neurosurg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11034","article-title":"Therapy-related leukemia and myelodysplasia: susceptibility and incidence","volume":"92","author":"Leone G","year":"2007","unstructured":"Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007, 92:1389-98. 10.3324\/haematol.11034","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy146","article-title":"Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide","volume":"21","author":"Yamashita AS","year":"2019","unstructured":"Yamashita AS, da Costa Rosa M, Borodovsky A, Festuccia WT, Chan T, Riggins GJ. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro Oncol. 2019, 21:189-200. 10.1093\/neuonc\/noy146","journal-title":"Neuro Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1408","article-title":"5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft","volume":"4","author":"Borodovsky A","year":"2013","unstructured":"Borodovsky A, Salmasi V, Turcan S, et al.. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013, 4:1737-47. 10.18632\/oncotarget.1408","journal-title":"Oncotarget"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa074","article-title":"5-Azacitidine in patients with IDH1\/2-mutant recurrent glioma","volume":"22","author":"Federici L","year":"2020","unstructured":"Federici L, Capelle L, Annereau M, et al.. 5-Azacitidine in patients with IDH1\/2-mutant recurrent glioma. Neuro Oncol. 2020, 22:1226-8. 10.1093\/neuonc\/noaa074","journal-title":"Neuro Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan SM","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, et al.. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015, 21:178-84. 10.1038\/nm.3788","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox183","article-title":"Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications","volume":"20","author":"Malta TM","year":"2018","unstructured":"Malta TM, de Souza CF, Sabedot TS, et al.. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro Oncol. 2018, 20:608-20. 10.1093\/neuonc\/nox183","journal-title":"Neuro Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr H","year":"2010","unstructured":"Noushmehr H, Weisenberger DJ, Diefes K, et al.. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010, 17:510-22. 10.1016\/j.ccr.2010.03.017","journal-title":"Cancer Cell"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02054-x","article-title":"Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers","volume":"40","author":"Yao K","year":"2021","unstructured":"Yao K, Liu H, Yin J, Yuan J, Tao H. Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers. J Exp Clin Cancer Res. 2021, 40:263. 10.1186\/s13046-021-02054-x","journal-title":"J Exp Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA1","article-title":"INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenid versus placebo in patients with residual or recurrent glade 2 glioma with IDH1\/2 mutation","volume":"41","author":"Mellinghoff I","year":"2023","unstructured":"Mellinghoff I, Bent VD, Blumenthal D, et al.. INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenid versus placebo in patients with residual or recurrent glade 2 glioma with IDH1\/2 mutation. J Clin Oncol. 2023, 41:17. 10.1200\/JCO.2023.41.17_suppl.LBA1","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/250932-favorable-radiographic-response-in-a-patient-with-an-oligodendroglioma-treated-with-azacitidine-and-venetoclax-for-acute-myeloid-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T20:17:58Z","timestamp":1717359478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/250932-favorable-radiographic-response-in-a-patient-with-an-oligodendroglioma-treated-with-azacitidine-and-venetoclax-for-acute-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,2]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.61540","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,2]]}}}